Since the patent has lapsed, the CSP is no longer relevant. What Novo Nordisk stands to lose in Canada and beyond The expiry of Novo Nordisks semaglutide patent in Canada might look small on paper, but the consequences could be substantial
The next major M&A opportunity may involve companies with differentiated oral GLP-1 assets, GLP-1/GIP dual agonists, amylin combinations, long-acting dosing platforms, or MASH-relevant metabolic therapies
These side effects are most frequent during the initial weeks and when increasing the dose but tend to improve over time
Complimentary Vitamin Enhancements - Boost your results with complimentary vitamin injections and supplemental wellness medications designed to support your energy, metabolism, and overall health
Efficacy of a vitamin/nutraceutical formulation for early-stage Alzheimer's disease: A 1-year, open label pilot study with a 16-month caregiver extension